|
Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Technical Data
| Formula | C11H10Cl2N4 |
|||
| Molecular Weight | 269.13 | CAS No. | 1609960-30-6 | |
| Solubility (25°C)* | In vitro | DMSO | 53 mg/mL (196.93 mM) | |
| Ethanol | 10 mg/mL (37.15 mM) | |||
| Water | Insoluble | |||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
||||
Preparing Stock Solutions
Biological Activity
| Description | TH287 is a potent and selective MTH1 (NUDT1) inhibitor with IC50 of 0.8 nM. | ||||
|---|---|---|---|---|---|
| Targets |
|
||||
| In vitro | TH287 selectively and effectively kill U2OS and other cancer cell lines with less toxic to several primary or immortalized cells, and induces oxidative DNA damage. [1] | ||||
| In vivo | In C57Bl/6 mice, TH287 (5 mk/kg, i.p.) causes a peak time and maximum concentration of 0.5 h and 0.82μM. [2] |
Protocol (from reference)
| Animal Study:[2] |
|
|---|
References
|
Selleck's TH287 has been cited by 5 publications
| Therapeutic targeting nudix hydrolase 1 creates a MYC-driven metabolic vulnerability [ Nat Commun, 2024, 15(1):2377] | PubMed: 38493213 |
| Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer [ Breast Cancer Res, 2022, 24(1):41] | PubMed: 35715861 |
| Disrupted mitochondrial homeostasis coupled with mitotic arrest generates antineoplastic oxidative stress [ Oncogene, 2021, 10.1038/s41388-021-02105-9] | PubMed: 34773075 |
| Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib. [ Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0507] | PubMed: 32229503 |
| MTH1 Inhibitor TH287 Suppresses Gastric Cancer Development Through the Regulation of PI3K/AKT Signaling. [ Cancer Biother Radiopharm, 2020, 10.1089/cbr.2019.3031] | PubMed: 32077746 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.